Genmab to Acquire ProfoundBio for $1.8 Billion

AbbVie to Acquire ImmunoGen for $10.1 Billion

November 30, 2023

Pharmaceuticals

AbbVie entered into a definitive agreement to acquire ImmunoGen, including its flagship ADC therapy ELAHERE (mirvetuximab soravtansine-gynx), in a deal valued at approximately $10.1 billion. The transaction is expected to close in mid-2024, subject to ImmunoGen shareholder approval, regulatory approvals, and other customary closing conditions.

Amgen Acquires Teneobio for $900M with Up to $1.6B in Milestones

July 27, 2021

Biotechnology

Amgen agreed to acquire clinical-stage biotechnology company Teneobio for $900 million in upfront cash plus potential contingent milestone payments up to $1.6 billion. The acquisition adds Teneobio's heavy-chain antibody discovery platform, bispecific/multispecific antibody technologies and a Phase 1 T-cell engager (TNB-585), strengthening Amgen's antibody research capabilities and oncology pipeline.

Pfizer Acquires Seagen for $43 Billion

December 14, 2023

Biotechnology

Pfizer completed its acquisition of Seagen, acquiring all outstanding common stock of Seagen for $229 per share in cash, valuing the enterprise at approximately $43 billion. The combination is intended to strengthen Pfizer’s oncology portfolio by adding Seagen’s proprietary antibody-drug conjugate (ADC) technology and in-line medicines.

Genmab A/S Acquires Merus N.V. via Tender Offer

December 12, 2025

Biotechnology

Genmab A/S, through its wholly owned purchaser Genmab Holding II B.V., completed a tender offer to acquire outstanding common shares of Merus N.V. for $97.00 per share and commenced a subsequent offering period. The acquisition adds Merus' lead late‑stage oncology asset petosemtamab to Genmab's portfolio, expanding its antibody therapeutics pipeline and expected to be accretive to EBITDA by 2029.

Sanofi Acquires Translate Bio in $3.2 Billion Deal

August 3, 2021

Biotechnology

Sanofi SA has entered into a definitive agreement to acquire all outstanding shares of clinical-stage mRNA therapeutics company Translate Bio for about $3.2 billion, or $38.00 per share in cash. The acquisition is intended to accelerate Sanofi’s application of messenger RNA (mRNA) to develop therapeutics and vaccines, building on an existing mRNA collaboration.

Sanofi to Acquire DR-0201 Program from Dren Bio

March 20, 2025

Biotechnology

Sanofi has agreed to acquire DR-0201, a CD20-directed bispecific myeloid cell engager, through purchase of Dren Bio’s affiliate Dren-0201 for an upfront $600 million and up to $1.3 billion in milestone payments. The deal, aimed at broadening Sanofi’s immunology pipeline and advancing deep B-cell depletion approaches, is expected to close in Q2 2025 subject to regulatory approvals; Dren Bio will continue to operate independently to advance its broader pipeline.